Literature DB >> 9154473

Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens.

C J VanCouwenberghe1, T B Farver, S H Cohen.   

Abstract

OBJECTIVE: To determine risk factors for patients whose cultures grew Stenotrophomonas maltophilia.
DESIGN: Retrospective case-control study of 60 patients with cultures positive for S maltophilia, matched by specimen site to 120 controls whose cultures grew other gram-negative aerobic bacteria.
SETTING: University medical center.
RESULTS: S maltophilia was identified from the following sites: respiratory (36), wound (13), urinary (6), blood (4), and cerebral spinal fluid (1). By univariate analysis, cases had a higher risk of exposure than controls for ampicillin (P < .001), gentamicin (P < .001), vancomycin (P = .001), metronidazole (P = .003), piperacillin (P = .007), cefotaxime (P = .014), ceftazidime (P = .017), ciprofloxacin (P = .030), tobramycin (P = .040), and chronic respiratory disease (P = .024). Length of time foreign objects were in place prior to positive culture differed significantly between cases and controls only for endotracheal tubes in patients with respiratory isolates (median number of days: 12.5 for cases, 5 for controls; P = .007). For patients with urinary tract infections, having a urinary catheter increased the odds of infection 10 times over controls. Exposures found by multivariate analysis to be significantly more prevalent in cases than controls included ampicillin, cefotaxime, erythromycin, gentamicin, metronidazole, piperacillin, tobramycin, chronic respiratory disease, and female gender. Odds ratios were > 1 indicating higher risk for cases, except for erythromycin, which had an odds ratio < 1.
CONCLUSIONS: The primary risk factor associated with isolation of S maltophilia was antibiotic use. For patients with pulmonary infections, chronic respiratory disease and length of time an endotracheal tube was in place also contributed to the risk. This suggests that judicious use of antibiotics may prevent some cases of S maltophilia infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154473     DOI: 10.1086/647618

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  10 in total

1.  Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Stenotrophomonas (Xanthomonas) maltophilia infection in necrotizing pancreatitis.

Authors:  K E Mönkemüller; D E Morgan; T H Baron
Journal:  Int J Pancreatol       Date:  1999-02

3.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

4.  Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis.

Authors:  Giovanni Di Bonaventura; Arianna Pompilio; Roberta Zappacosta; Francesca Petrucci; Ersilia Fiscarelli; Cosmo Rossi; Raffaele Piccolomini
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

5.  Stenotrophomonas maltophilia bacteremia after living donor liver transplantation: Report of a case.

Authors:  Noboru Harada; Yuji Soejima; Akinobu Taketomi; Tomoharu Yoshizumi; Hideaki Uchiyama; Yoshihiko Maehara
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

6.  Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.

Authors:  George Samonis; Drosos E Karageorgopoulos; Sofia Maraki; Panagiotis Levis; Dimitra Dimopoulou; Nikolaos A Spernovasilis; Diamantis P Kofteridis; Matthew E Falagas
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

7.  Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

Authors:  S Valdezate; A Vindel; L Maiz; F Baquero; H Escobar; R Cantón
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

8.  Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.

Authors:  Saad Nseir; Christophe Di Pompeo; Hélène Brisson; Florent Dewavrin; Stéphanie Tissier; Maimouna Diarra; Marie Boulo; Alain Durocher
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

9.  Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.

Authors:  Arun P Nair; Sreethish Sasi; Muna Al Maslamani; Abdullatif Al-Khal; Kadavil Chacko; Anand Deshmukh; Mohammed Abukhattab
Journal:  Cureus       Date:  2022-03-17

10.  Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients.

Authors:  Worachart Insuwanno; Pattarachai Kiratisin; Anupop Jitmuang
Journal:  Infect Drug Resist       Date:  2020-05-28       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.